Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) as Second Line Therapy in Patients With Recurrent Platinum Sensitive Ovarian Cancer

NCT00719212 is registered in ClinicalTrials.gov with Translational Research in Oncology as lead sponsor.

NCT NCT00719212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00719212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) as Second Line Therapy in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Lead sponsor
Translational Research in Oncology
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
May 31, 2013
Enrollment
61 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms